| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
MT-44 exhibits potent anti-proliferative activity against TNBC cells MDA-MB-231 and MDA-MB-468, with IC50 values of 66.5 nM and 148.2 nM, respectively [1]. MT-44 (0.25-1.0 μM, 12-48 h) concentration-dependently inhibits MDA-MB-231 cell migration and induces G2/M phase arrest [1]. MT-44 (0.05-0.5 μM) significantly inhibits MDA-MB-231 cell colony formation and invasion [1]. MT-44 (0.5-2.0 μM, 24 h) concentration-dependently induces MDA-MB-231 cell apoptosis, promotes autophagy, and increases ROS accumulation [1]. MT-44 (0.5-2.0 μM, 24 h) downregulated the phosphorylation levels of p-P70S6K, p-Akt, and p-4EBP1 in MDA-MB-231 cells and upregulated phosphorylated proteins in the cGAS/STING pathway [1].
|
|---|---|
| ln Vivo |
MT-44 (10-20 mg/kg, intravenously every 3 days for 15 days) significantly inhibited tumor growth in a female BALB/c nude mouse MDA-MB-231 xenograft model [1].
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: MDA-MB-231 cells Tested Concentrations: 0.5, 1 and 2 μM Incubation Duration: 24 h Experimental Results: Increased apoptotic cells. Upregulated the expression of γ-H2AX and the ratio of BAX/BCL2. |
| Animal Protocol |
Animal/Disease Models: Female BALB/c nude mice with MDA-MB-231 xenografts[1]
Doses: 10 and 20 mg/kg Route of Administration: Intravenously injection, once every 3 days for 15 days Experimental Results: Showed tumor growth inhibition rates (TGI) of 38.64% and 72.73%. Had obvious organ toxicity. Downregulated phosphorylated proteins of the mTOR pathway in tumor tissues. Activated the cGAS/STING pathway, increased NK cell infiltration, and reduced regulatory T cells and tumor-associated macrophages. |
| References |
| Molecular Formula |
C26H23N5O4
|
|---|---|
| Molecular Weight |
469.49
|
| CAS # |
2966790-70-3
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1300 mL | 10.6499 mL | 21.2997 mL | |
| 5 mM | 0.4260 mL | 2.1300 mL | 4.2599 mL | |
| 10 mM | 0.2130 mL | 1.0650 mL | 2.1300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
